Clinical trials: High-risk Medications
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Stroke, Transient Ischemic Attack (TIA)
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic…
- Trial name
- CYP-FAST (NCT06943586)
- Testing
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Drug Resistant Epilepsy
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Evaluation of the role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy. Early detection of the prognosis might help in guiding patients for proper management and treatment…
- Trial name
- NCT05555537
- Testing
- MiRNA223 and High mobility group box1(HMGB1)
- Volunteers
- 90 people
- Sponsor
- Assiut University
Tuberculosis Active
Video-observed Therapy for Active Tuberculosis: a Feasibility Study
Tuberculosis (TB) is still present in Switzerland, and concerns mainly foreign-born subjects. Monitoring compliance to treatment by Directly Observed Therapy (DOT) is strongly encouraged by the World Health Organization (WHO).
- Trial name
- NCT06574529
- Testing
- Video-observed therapy (vDOT)
- Where
- Switzerland
- Volunteers
- 51 people
- Sponsor
- Ligue Pulmonaire Genevoise
Reproductive Behavior, Sexual Behavior
Reducing Teen Pregnancy in the Emergency Department
This study will determine the feasibility, acceptability, and potential efficacy of an emergency department-based pregnancy prevention intervention targeting sexually active adolescent female emergency department patients.
- Conditions
- Reproductive Behavior, Sexual Behavior, Adolescent Behavior, Contraception
- Trial name
- ERICA (NCT03866811)
- Testing
- Dr. Erica
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Columbia University
High Risk Coronary Artery Disease
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center, crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of rosuvastatin, and to assess the relative bioavailability…
- Trial name
- NCT02963116
- Testing
- AZD5718 IR tablet, AZD5718 oral suspension, Rosuvastatin tablet
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pain, Chronic, Prescription Drug Abuse (Not Dependent)
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to…
- Trial name
- LEAP (NCT03947749)
- Where
- 2 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of Florida
Infant Newborn Disease
Multidrug Resistant Gram-negative Pathogen Infections in High Risk Neonates in the Northeast of Mexico
The main objective of this project is to establish a prospective cohort to measure the Gram-negative infection burden in neonates under special care in a regional referral hospital, and to characterize all microorganisms isolates…
- Trial name
- InfGNMDR-Neo (NCT04812847)
- Testing
- Identification of MDR characteristics
- Where
- Mexico
- Volunteers
- 597 people
- Sponsor
- Instituto Tecnologico y de Estudios Superiores de Monterey
Malaria
Kilimanjaro IPTi Drug Options Trial
Malaria and anaemia are major causes of morbidity and mortality in children in sub-Saharan Africa. Administration of three courses of sulfadoxine/pyrimethamine (SP) as intermittent preventive treatment (IPTi) to infants when they…
- Trial name
- NCT00158574
- Testing
- sulphadoxine-pyrimethamine, mefloquine, Chlorproguanil-dapsone
- Where
- Tanzania
- Volunteers
- 2,419 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Hyperlipidemia
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density…
- Trial name
- MENDEL-2 (NCT01763827)
- Testing
- Evolocumab, Ezetimibe
- Where
- 83 sites in United States, Australia and 8 more
- Volunteers
- 615 people
- Sponsor
- Amgen
Epilepsy
Assessment of MRI-guided HIFU for Patients With Drug-resistant Focal Epilepsy
The goal of this clinical trial is to assess the feasibility, safety, and tolerance of MRI-guided High-Intensity Focused Ultrasound (HIFU) for the treatment of drug-resistant focal epilepsy in adult patients with MRI-visible…
- Trial name
- EPIFUS (NCT07591350)
- Testing
- MR-guided HIFU thermoablation, EEG, MRI
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Patient Readmission
Transition cAre inteRvention tarGeted to High-risk patiEnts To Reduce rEADmission
Hospital rehospitalizations within 30 days are frequent and represent a burden for the patients, but also for the entire health care system.
- Trial name
- TARGET-READ (NCT03496896)
- Testing
- TARGET
- Where
- 4 sites in Switzerland
- Volunteers
- 1,393 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Chronic Obstructive Pulmonary Disease
This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose
AZD5069 is a new drug being tested for the possible treatment of people with chronic obstructive pulmonary disease (COPD). This is not the first time that AZD5069 will be administered to humans in clinical trials.
- Trial name
- NCT01083238
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ultrasonography, Breast Neoplasm Female
Intelligent Remote Intervention for High-risk Breast Cancer Populations
The goal of this clinical trial is to compare the effects of modern remote health intervention regime with traditional in-person intervention strategies for high-risk breast cancer groups that with BI-RADS 3 or higher nodules.
- Conditions
- Ultrasonography, Breast Neoplasm Female, Breast Carcinoma, Health Education
- Trial name
- NCT06193707
- Testing
- the Remote Intervention, the Traditional Intervention
- Volunteers
- 1,250 people
- Sponsor
- Qianfoshan Hospital
Acute Coronary Syndrome
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone…
- Trial name
- NCT05750758
- Testing
- rivaroxaban
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Urinary Bladder Neoplasms
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
- Trial name
- CheckMate 9UT (NCT03519256)
- Testing
- Nivolumab, BCG, BMS-986205
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease (CAD)
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting…
- Trial name
- TRIGGER-PCI (NCT00910299)
- Testing
- Prasugrel, Clopidogrel
- Where
- 27 sites in United States, Germany
- Volunteers
- 423 people
- Sponsor
- Eli Lilly and Company
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood.
- Trial name
- NCT00000895
- Testing
- Nelfinavir mesylate, Nevirapine, Azithromycin
- Where
- 26 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Hepatitis C
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PegIntron plus Rebetol combination therapy administered to patients with chronic hepatitis C.
- Trial name
- NCT00724230
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 505 people
- Sponsor
- Merck Sharp & Dohme LLC
Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs
Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity
High-potency benzodiazepines have strong anxiolytic effects accompanied by significant adverse effects including impaired cognitive function, drowsiness, dizziness and impaired motoric abilities.
- Trial name
- NCT03829839
- Testing
- Oxytocin, Lorazepam 1 mg
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn